Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2025)
Historic Profit After Tax for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$34.4 million.
- Amylyx Pharmaceuticals' Profit After Tax rose 5270.41% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 4246.57%. This contributed to the annual value of -$301.7 million for FY2024, which is 71241.5% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' Profit After Tax stood at -$34.4 million, which was up 5270.41% from -$41.4 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' Profit After Tax's 5-year high stood at $22.1 million during Q2 2023, with a 5-year trough of -$118.8 million in Q1 2024.
- For the 5-year period, Amylyx Pharmaceuticals' Profit After Tax averaged around -$34.2 million, with its median value being -$35.9 million (2025).
- Per our database at Business Quant, Amylyx Pharmaceuticals' Profit After Tax skyrocketed by 14082.71% in 2023 and then crashed by 765200.25% in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Profit After Tax stood at -$28.3 million in 2021, then crashed by 50.66% to -$42.7 million in 2022, then soared by 111.08% to $4.7 million in 2023, then plummeted by 893.62% to -$37.5 million in 2024, then increased by 8.42% to -$34.4 million in 2025.
- Its last three reported values are -$34.4 million in Q3 2025, -$41.4 million for Q2 2025, and -$35.9 million during Q1 2025.